Literature DB >> 12089293

Accuracy of results obtained by performing a second ligase chain reaction assay and PCR analysis on urine samples with positive or near-cutoff results in the LCx test for Chlamydia trachomatis.

S Castriciano1, K Luinstra, D Jang, J Patel, J Mahony, J Kapala, M Chernesky.   

Abstract

Nucleic acid amplification assays such as the ligase chain reaction and PCR have encountered reproducibility problems. The initial extract and a newly extracted aliquot of urine specimens (n = 120) which had signal-to-cutoff (S/CO) ratios above 0.80 by the LCx Chlamydia assay were retested. Nucleic acid was extracted from an additional urine sample for testing by the AMPLICOR PCR Chlamydia assay. Fifteen percent (18 of 120) of the urine specimens were negative by all repeat tests (initial mean S/CO ratio by the LCx Chlamydia assay, 0.93; S/CO ratio range, 0.80 to 3.30). Repeat testing of the 102 specimens with possible positive results by the LCx Chlamydia assay by use of the initially extracted aliquot confirmed the results for 95 (93.1%) of the specimens; repeat testing of a newly extracted aliquot confirmed the results for 87 (85.3%) of the specimens. Twenty specimens had discordant results by the two repeat LCx Chlamydia assays. A total of 78 of 102 (76.5%) of the specimens were positive by the AMPLICOR PCR, and the AMPLICOR PCR confirmed the results for 82.1% (78 of 95) and 89.6% (78 of 87) of the specimens positive by the two repeat LCx Chlamydia assays, respectively. Some of the discrepancies observed by multiple repeat tests may have been due to specimen mislabeling or contamination during performance of the procedure rather than to the LCx Chlamydia assay. Both assays suffered from a lack of reproducibility on repeat testing with a small proportion of specimens, probably due to the presence of low levels of DNA, the presence of variable amounts of amplification inhibitors, and the loss of DNA during extraction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089293      PMCID: PMC120557          DOI: 10.1128/JCM.40.7.2632-2634.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens.

Authors:  M Smieja; J B Mahony; C H Goldsmith; S Chong; A Petrich; M Chernesky
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Reproducibility problems with the Abbott laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  A M Gronowski; S Copper; D Baorto; P R Murray
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by beta-globin gene amplification.

Authors:  F Coutlée; M de Ladurantaye; C Tremblay; J Vincelette; L Labrecque; M Roger
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix.

Authors:  J Schachter; W E Stamm; T C Quinn; W W Andrews; J D Burczak; H H Lee
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

5.  Reproducibility problems with the AMPLICOR PCR Chlamydia trachomatis test.

Authors:  E M Peterson; V Darrow; J Blanding; S Aarnaes; L M de la Maza
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

6.  Performance of transcription-mediated amplification and ligase chain reaction assays for detection of chlamydial infection in urogenital samples obtained by invasive and noninvasive methods.

Authors:  A Stary; E Schuh; M Kerschbaumer; B Götz; H Lee
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

7.  Urine specimens from pregnant and nonpregnant women inhibitory to amplification of Chlamydia trachomatis nucleic acid by PCR, ligase chain reaction, and transcription-mediated amplification: identification of urinary substances associated with inhibition and removal of inhibitory activity.

Authors:  J Mahony; S Chong; D Jang; K Luinstra; M Faught; D Dalby; J Sellors; M Chernesky
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

8.  Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction.

Authors:  M A Chernesky; D Jang; H Lee; J D Burczak; H Hu; J Sellors; S J Tomazic-Allen; J B Mahony
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

9.  Diagnosis of Chlamydia trachomatis urethritis in men by polymerase chain reaction assay of first-catch urine.

Authors:  J E Bauwens; A M Clark; M J Loeffelholz; S A Herman; W E Stamm
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

10.  Direct detection of Chlamydia trachomatis in urine specimens from symptomatic and asymptomatic men by using a rapid polymerase chain reaction assay.

Authors:  G Jaschek; C A Gaydos; L E Welsh; T C Quinn
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

  10 in total
  10 in total

1.  Development and validation of a rotor-gene real-time PCR assay for detection, identification, and quantification of Chlamydia trachomatis in a single reaction.

Authors:  Hamid Jalal; Hannah Stephen; Martin D Curran; Janet Burton; Michelle Bradley; Christopher Carne
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Confirming positive results of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: all NAATs are not created equal.

Authors:  J Schachter; E W Hook; D H Martin; D Willis; P Fine; D Fuller; J Jordan; W M Janda; M Chernesky
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised.

Authors:  Julius Schachter; Joan M Chow; Holly Howard; Gail Bolan; Jeanne Moncada
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  External quality assessment for detection of Chlamydia trachomatis.

Authors:  V J Chalker; H Vaughan; P Patel; A Rossouw; H Seyedzadeh; K Gerrard; V L A James
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Comparison of the APTIMA CT and GC assays with the APTIMA combo 2 assay, the Abbott LCx assay, and direct fluorescent-antibody and culture assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  B Boyadzhyan; T Yashina; J H Yatabe; M Patnaik; C S Hill
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 6.  Reproducibility and specificity concerns associated with nucleic acid amplification tests for detecting Chlamydia trachomatis.

Authors:  A Hadgu; M Sternberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-19       Impact factor: 3.267

7.  Reproducibility of positive test results in the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Elizabeth E Culler; Angela M Caliendo; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

8.  Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States.

Authors:  April L Harkins; Erik Munson
Journal:  ISRN Obstet Gynecol       Date:  2011-06-12

9.  Diagnostic accuracy of a prototype point-of-care test for ocular Chlamydia trachomatis under field conditions in The Gambia and Senegal.

Authors:  Emma M Harding-Esch; Martin J Holland; Jean-François Schémann; Sandra Molina; Isatou Sarr; Aura A Andreasen; Chrissy h Roberts; Ansumana Sillah; Boubacar Sarr; Edward F Harding; Tansy Edwards; Robin L Bailey; David C W Mabey
Journal:  PLoS Negl Trop Dis       Date:  2011-08-02

Review 10.  Advances in ligase chain reaction and ligation-based amplifications for genotyping assays: Detection and applications.

Authors:  Abdullah A Gibriel; Ola Adel
Journal:  Mutat Res Rev Mutat Res       Date:  2017-05-02       Impact factor: 5.657

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.